Holgersson G, Ekman S, Reizenstein J, Bergqvist M, Pontén F, Uhlén M, Magnusson K, Jonnalagadda P, Asplund A, Strömberg S, Linder A, Blomquist E, Liljeholm M, Lödén B, Hellström K, Bergström S
Cancer Genomics Proteomics 7 (1) 1-7 [2010-02-26; online 2010-02-26]
To explore the usefulness of the expression of five potential cancer biomarkers in predicting outcome in patients with laryngeal cancer. In the present study, the Swedish National Cancer Registry databases were used to identify patients with laryngeal cancer diagnosed during the years 1978-2004 in the Uppsala-Orebro region and treated with radiotherapy. The expression of Ki-67, MutS homolog 2, (MSH2), p53, B-cell CLL/lymphoma 2 (Bcl-2) and cyclin D1 in the cancer cells was assessed immunohistochemically using tissue microarrays (TMAs) and its predicitve value on survival and relapse was analyzed using Cox regression models. A total of 39 patients were included in the present study. Nuclear MSH2 staining was statistically significantly correlated to Ki-67 expression (p=0.022). However, univariate and multivariate Cox analyses showed no statistically significant association between the expression of the investigated biomarkers and overall survival or relapse. The present exploratory study does not show any significant predictive value of the biomarkers examined with respect to survival or relapse. However, with larger patient cohorts, we believe that protein profiling using TMAs and immunohistochemistry is a feasible strategy for prognostic and predictive biomarker screening in laryngeal cancer.